**Uroplakin II**
Concentrated and Prediluted Monoclonal Antibody
902-3051-082622

### Available Product Formats

<table>
<thead>
<tr>
<th>Format</th>
<th>Catalog Number</th>
<th>Description</th>
<th>Dilution</th>
<th>Diluent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentrate</td>
<td>ACR 3051 A, C</td>
<td>0.1, 1.0 mL</td>
<td>1:100</td>
<td>Van Gogh Yellow</td>
</tr>
<tr>
<td>Predilute</td>
<td>APR 3051 AA</td>
<td>6.0 mL</td>
<td>Ready-to-use</td>
<td>N/A</td>
</tr>
<tr>
<td>UltraLine – For BenchMark</td>
<td>AVR 3051 KG, KG25</td>
<td>6.0, 25 mL</td>
<td>Ready-to-use</td>
<td>N/A</td>
</tr>
<tr>
<td>Q Series – For Leica BOND-III</td>
<td>ALR 3051 G7</td>
<td>7.0 mL</td>
<td>Ready-to-use</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Intended Use:
For Research Use Only. Not for use in diagnostic procedures.

### Summary and Explanation:
Uroplakin II is a 15 kDa protein component of urothelial plaques, which enhance the permeability barrier of the urothelium (1). Studies have shown Uroplakin II mRNA was expressed in bladder cancer tissues and peripheral blood of patients with primary and metastatic urothelial carcinoma of the bladder (2-4). With the exception of bladder and ureter, Uroplakin II [BC21] was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostate cancer and renal cell carcinoma.

U.S. Patent 9,429,577 and patents pending.

### Principle of Procedure:
Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one-step or two-step detection procedure can be applied. A one-step procedure will feature an enzyme labeled polymer that binds the primary antibody. A two-step procedure will feature a linker antibody added to bind to the primary antibody. An enzyme-labeled polymer is then added to bind the linker antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction.

### Source:
Mouse monoclonal

### Species Reactivity:
Human; others not tested

### Clone:
BC21

### Isotype:
IgG1/kappa

### Protein Concentration:
Call for lot specific Ig concentration.

### Epitope/Antigen:
Residues 36-50 of human Uroplakin II

### Cellular Localization:
Cytoplasmic and membrane

### Positive Tissue Control:
Normal bladder or urothelial carcinoma of the bladder

### Known Applications:
Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

### Supplied As:
Buffer with protein carrier and preservative

**For AVR3051K:**
Uroplakin II (AVR3051)
V-Blocker (BR4R001)

### Storage and Stability:
Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

### Staining Protocol Recommendations (intelliPATH FLX® and manual use):

**Peroxidase Block:** Block for 5 minutes with Peroxidazed 1.

**Pretreatment:** Perform heat retrieval using Reveal Decloaker. Refer to the Reveal Decloaker product data sheet for specific instructions.

**Protein Block (Optional):** Incubate for 5-10 minutes at RT with Background Punisher.

**Primary Antibody:** Incubate for 30 minutes at RT.

**Probe:** Incubate for 10 minutes at RT with a secondary probe.

**Polymer:** Incubate for 10-20 minutes at RT with a tertiary polymer.

**Chromogen:** Incubate for 5 minutes at RT with Biocare’s DAB - OR - Incubate for 5-7 minutes at RT with Warp Red.

**Counterstain:** Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha’s Bluing Solution for 1 minute. Rinse with deionized water.

**Technical Note:** This antibody, for intelliPATH FLX and manual use, has been standardized with MACH 4 detection system. Use TBS for washing steps.

### Staining Protocol Recommendations (Ventana BenchMark ULTRA):
AVR3051 is intended for use with the BenchMark ULTRA. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

- **Using ultraView on XT / ULTRA:**

  **Template/Detection:** ultraView DAB

  **Pretreatment Protocol:** CC1 Mild

  **Primary Antibody:** 32 minutes, 37°C

  **ultraBlock (V-Blocker BRR4001):** Incubate for 4 minutes (with appropriate Option # registered by user)

  **V-Blocker** is recommended to be applied prior to any detection system.

- **Using OptiView on ULTRA:**

  **Template/Detection:** OptiView DAB IHC

  **Pretreatment Protocol:** CC1 32 minutes

  **Peroxidase:** Pre-Primary Peroxidase Inhibitor

  **Primary Antibody:** 8 minutes, 36°C

### Staining Protocol Recommendations (Q Series – For Leica BOND-III):
ALR3051 is intended for use with the Leica BOND-III. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

**Protocol Name:** IHC Protocol F

**Detection:** Bond Polymer Refine

**HIER:** 20 min with ER2

**Peroxide Block:** 5 min

**Marker (Primary Antibody):** 15 min

**Post Primary:** 8 min

**Polymer:** 8 min

**Mixed DAB Refine:** 10 min

**Hematoxylin:** 5 min

### Limitations:
This product is provided for Research Use Only (RUO) and is not for use in diagnostic procedures. Suitability for specific applications may vary and it is the responsibility of the end user to determine the appropriate application for its use.

### Precautions:
1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC.

   Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide buildup-in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (5)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contact with skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (6)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

5. Do not use reagent after the expiration date printed on the vial.

6. The SDS is available upon request and is located at http://biocare.net.
Uroplakin II
Concentrated and Prediluted Monoclonal Antibody
902-3051-082622

Technical Support:
Contact Biocare’s Technical Support at 1-800-542-2002 for questions regarding this product.

References:

Ultraline antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Ventana Medical Systems, Inc or Roche. Biocare, Ventana and Roche are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.

Q Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Leica Biosystems. Biocare and Leica Biosystems are not affiliated, associated or related in any way. Leica, Leica Biosystems, BOND-MAX and BOND-III are trademarks of Leica Biosystems.